Neutralizing anti-DKK1 antibodies also hold therapeutic potential in combination with chemotherapy as recently demonstrated with a functional reagent antibody, AF1096 (R&D Systems), where improved therapeutic efficacy of paclitaxel in two murine models of breast cancer was reported in addition to the alleviation of paclitaxel-induced peripheral neuropathy [59]. Here, DKK1 is linked to peripheral neuropathy.